Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients

Summary

This is a multicentre study examining the effectiveness of angiotension converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) or a combination of both in reducing the rate of decline in residual renal function (RRF) in continuous ambulatory peritoneal dialysis (CAPD) patients.

Conditions

• Renal Function Disorder

Interventions

DRUG

Benazepril

Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

DRUG

Valsartan

Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

DRUG

Benazepril+Valsartan

Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

DRUG

Control

Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

Sponsors & Collaborators

• Sun Yat-sen University

  lead OTHER

Principal Investigators

• Xueqing Yu, M.D. & Ph.D. · 1st Affiliated Hospital, Sun Yat-Sen University

• Jianbo Liang, M.D. · 2nd Affiliated Hospital, Guangzhou Medical College

• Yunhua Liao, M.D. · 1st Affiliated Hospital, Guangxi Medical University

• Xinzhou Zhang, M.D. & Ph.D. · Shenzhen People's Hospital

• Fei Xiong, M.D. · Wuhan No.1 Hospital

• Hao Zhang, M.D. · 3rd Xiangya Hospital, Central South University

• Ping Fu, M.D. & Ph.D. · West China Hospital

• Yonggui Wu, M.D.& Ph.D. · 1st Affiliated Hospital, Anhui Medical University

• Minghui Zhao, M.D.&Ph.D. · Peking University First Hospital

• Xuewang Li, M.D. · Peking Union Medical College Hospital

• Li Hao, MD · 2nd Affiliated Hospital, Anhui Medical University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-09-30

Primary Completion

2014-10-31

Completion

2014-10-31

Countries

• China

Study Locations